Learn about the latest financial trends and strategies in our comprehensive article written by a financial expert.
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Altimmune (ALT – Research Report) yesterday and set a price target of ...
B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating ...
Research analysts at B. Riley increased their FY2024 earnings estimates for FormFactor in a research note issued on Monday, January 27th. B. Riley analyst C. Ellis now forecasts that the semiconductor ...
In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...
President Donald Trump plans to sign the Laken Riley Act into law as his administration's first piece of legislation.
LOS ANGELES, Jan. 21, 2025 /PRNewswire/ -- B. Riley Financial, Inc. (NASDAQ: RILY) ("B. Riley" or the "Company"), a diversified financial services company, today ...
I have covered B. Riley Financial, Inc. or "B. Riley" (NASDAQ:RILY, NASDAQ:RILYL, NASDAQ:RILYP, NASDAQ:RILYM, NASDAQ:RILYK, NASDAQ:RILYN, NASDAQ:RILYG, NASDAQ:RILYT ...
B. Riley Financial Inc. suspended dividends on a pair of its preferred shares, holding off on cash payments to some investors ...